IART Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation Announces Virtual-Only Format for Its 2020 Annual Meeting of Stockholders

Integra LifeSciences Holdings Corporation Announces Virtual-Only Format for Its 2020 Annual Meeting of Stockholders

PRINCETON, N.J., April 23, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that its 2020 Annual Meeting of Stockholders (the “Meeting”) location will change from its headquarters to a virtual meeting by remote communication. As noted in our Proxy Statement, the Company determined to change the location from a physical meeting to a virtual meeting due to the continuing health concerns regarding the COVID-19 pandemic, restrictions on gathering issued by the State of New Jersey and the U.S. Centers for Disease Control and Prevention, and to continue to support the health and well-being of our employees, stockholders, and directors. No stockholders will be permitted to attend the 2020 Annual Meeting in person.

The meeting will be held at the previously announced date and time, May 13, 2020 at 9:00 a.m., Eastern Time. The proxy card included with the proxy materials previously distributed will not be updated to reflect the change in location and may continue to be used to vote your shares in connection with the Meeting. Whether or not you plan to attend the Annual Meeting, the Company urges you to vote and submit your proxy in advance of the meeting by the methods described in the proxy materials for the Meeting. Please follow the instructions below on how to attend the Meeting.

In order to participate in the Meeting or vote during the Meeting, stockholders must enter the 16-digit digital control number found on their proxy cards by logging on to on the day of the Meeting. Online access to the webcast will be open 15 minutes prior to the Meeting. The Meeting will begin promptly at 9:00 a.m., Eastern Time, on Wednesday May 13, 2020. We encourage you to log on early. 

Stockholders attending the Meeting will have the opportunity to submit questions during the meeting that are pertinent to the matters to be voted on at the Meeting through the virtual platform by following the online instructions. Stockholders that have already voted do not need to vote again. A list of the stockholders of record will be available for inspection by stockholders on the virtual meeting website during the meeting and will also be available for inspection by any stockholder for any purpose germane to the Meeting for ten days prior to the Meeting by contacting Investor Relations using the contact information below.

Please call the technical support number that will be posted on the virtual meeting login page for any technical difficulties encountered while logging in to the meeting.

About Integra LifeSciences

Integra LifeSciences is a global leader in regenerative technologies, neurosurgical and extremity orthopedic solutions dedicated to limiting uncertainty for clinicians, so they can focus on providing the best patient care. Integra offers a comprehensive portfolio of high quality, leadership brands that include AmnioExcel®, Bactiseal®, Cadence®, Certas™, Codman®, CUSA®, DuraGen®, DuraSeal®, ICP Express®, Integra®, MediHoney®, MicroFrance®, PriMatrix®, Salto Talaris®, SurgiMend®, TCC-EZ®, Titan™ and VersaTru™.  For the latest news and information about Integra and its products, please visit .

Investor Relations Contact:

Michael Beaulieu

Director, Investor Relations

(609) 750-2827

Media Contact:

Laurene Isip

Senior Director, Global Corporate Communications

(609) 750-7984

EN
23/04/2020

Underlying

Reports on Integra LifeSciences Holdings Corporation

 PRESS RELEASE

Integra LifeSciences Reports First Quarter 2025 Financial Results

Integra LifeSciences Reports First Quarter 2025 Financial Results PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2025. First Quarter 2025 Highlights First quarter revenues of $382.7 million increased 3.7% on a reported basis and decreased 3.5% on an organic basis compared to the prior year. First quarter GAAP earnings per diluted share of $(0.33), compared to $(0.04) in the prior year; adjusted earnings per diluted share of $0.41, compared to $0.55...

 PRESS RELEASE

Integra LifeSciences to Host First Quarter 2025 Financial Results Conf...

Integra LifeSciences to Host First Quarter 2025 Financial Results Conference Call on May 5, 2025 PRINCETON, N.J., April 18, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: IART), a leading global medical technology company, will release first quarter 2025 financial results on Monday, May 5, 2025, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company’s website at . For those planning to participate on the call, register  to receive dial-in detail...

 PRESS RELEASE

Integra LifeSciences to Present at the Oppenheimer 35th Annual Healthc...

Integra LifeSciences to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference PRINCETON, N.J., March 13, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: IART), a leading global medical technology company, announced today that Mojdeh Poul, chief executive officer and Lea Knight, chief financial officer will present at the 35th Annual Oppenheimer Healthcare MedTech & Services Conference on March 17, 2025 at 10:00am ET. A live webcast of the presentation will be available on the Integra LifeSciences investor relations website at . About Integra LifeSciencesAt Integra LifeScien...

 PRESS RELEASE

Integra LifeSciences Reports Fourth Quarter and Full-Year 2024 Financi...

Integra LifeSciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides 2025 Financial Guidance PRINCETON, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Reported revenues were $442.6 million, representing an increase of 11.5% on a reported basis and an increase of 3.5% on an organic basis compared to the fourth quarter 2023. GAAP earnings per diluted share were $0.25, compared to $0.25 in the fourth quarter 2023. Adjusted earnings per dilut...

 PRESS RELEASE

Integra LifeSciences to Host Fourth Quarter and Full Year 2024 Financi...

Integra LifeSciences to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on February 25, 2025 PRINCETON, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: IART), a leading global medical technology company, will release fourth quarter and full year 2024 financial results on Tuesday, February 25, 2025, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company’s website at . For those planning to participate on...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch